Which Pot Stocks Can Capitalize on the Cannabis 2.0 Revolution?

The Cannabis 2.0 revolution is now a reality. Find out how to profit with stocks like HEXO Corp. (TSX:HEXO)(NYSE:HEXO) and Canopy Growth Corp (TSX:WEED)(NYSE:CGC).

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The Cannabis 2.0 revolution is here. On October 17, cannabis concentrates and edibles became legal in Canada. This comes a year after full recreational legalization of fresh and dried cannabis flowers, oil, plants, and seeds.

According to international accounting firm Deloitte, “The speed with which Canada’s cannabis industry has evolved over the past 18 months has been truly remarkable.” The legalization of new form factors like edibles and concentrates adds a new layer of growth that could add significant long-term growth to the industry. “The introduction of these new products is creating new opportunities in product mixes, reaching new cannabis consumers not fully comfortable with traditional consumption methods currently available,” Deloitte noted in a recent research report.

If you want to capitalize on the biggest marijuana opportunity since legalization, here’s how to invest.

Opening doors

Not every company is prepared to seize the Cannabis 2.0 opportunity. In fact, many pot companies have zero exposure, possibly because they’re too focused on ramping dry flower production. Over the next few quarters, a number of cannabis producers are expected to bring their first production online. That takes a tonne of money and resources, meaning the majority aren’t yet looking to capitalize on adjacent markets.

But just because most pot stocks aren’t ready to capitalize doesn’t mean there aren’t some great investable opportunities. HEXO (TSX:HEXO)(NYSE:HEXO) is a great example.

According to HEXO’s management team, the company’s goal is “to become the premier Branded Ingredients For Food (IFF) cannabis company.” Note that it’s not trying to grow and sell simple, commoditized cannabis flowers. Instead, it’s focused on the market that opened up on October 17: edibles.

HEXO has already become the first cannabis company to join the Food & Consumer Products of Canada industry association and forged a deal with Molson Coors Canada to create cannabis-infused beverages. Over time, the company wants to secure more Fortune 500 partnerships to target cosmetics, health and wellness, and other verticals. When it comes to capitalizing on Cannabis 2.0, HEXO may have the lead.

Trust experience

The only other company with a greater lead may be Canopy Growth (TSX:WEED)(NYSE:CGC). That’s because it recently partnered with $40 billion brand behemoth Constellation Brands, owner of iconic brands like Corona, Model, Pacifico, Robert Mondavi wines, Svedka vodka, and more. If there’s any company that can figure out how to turn commoditized ingredients into a global brand powerhouse, it would be Constellation.

With Constellation as a partner, Canopy has access to something few competitors can tap: billions in cash. As of last quarter, Canopy had roughly $3 billion in dry powder. Only a handful of pot stocks have this kind of capital. It’s a huge advantage when building out next-gen cannabis products like edibles and beverages.

And unlike the competition, Canopy already has a growing base of repeat customers. This fiscal year, the company should generate more than $400 million in sales. Next year, revenue should double. Long term, if Canopy can nail its consumables business, there could be even more upside.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of Molson Coors Brewing. The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »